Sign in
GTBP Stock Price, Chart, Stats & News
GT Biopharma, Inc.
Save
5.46M
Market cap
–
Current P/E
17.33x
Forward P/E
GTBP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -349.79% |
ROE | -898.42% |
D/E | – |
Interest coverage ratio | -97.81x |
GTBP valuation
P/E | – |
P/S | – |
P/B | 0.39x |
P/CF | -0.17x |
P/FCF | -0.34x |
P/OCF | -0.17x |
PEG | 0.00x |
EV multiple | -0.32x |
About
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials.
Similar securities
Based on sector and market capitalization
Report issue